ERBB2 and breast carcinoma: DESTINY-Breast03 is an open label, multicenter, phase III trial of 524 patients with unresectable or metastatic Her2-positive breast cancer who had previously received trastuzumab and a taxane in the advanced or metastatic setting [2].